Treatment with PD-1 inhibitors in NSCLC beyond disease progression: Impact on symptoms and cost.

被引：1
|
作者：
Moskovitz, Mor Tal
Matthews, Priscilla M.
Pavel, Alexandra M.
Xu, Wei
Bradbury, Penelope Ann
Liu, Geoffrey
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 05期
关键词：
D O I：
10.1200/JCO.2018.36.5_suppl.174
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
174
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PD-1 Inhibitors Raise Survival in NSCLC
    不详
    CANCER DISCOVERY, 2014, 4 (01) : 6 - 6
  • [2] Beyond chemotherapy for advanced disease-the role of EGFR and PD-1 inhibitors
    Gu, Weijie
    Zhu, Yao
    Ye, Dingwei
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2017, 6 (05) : 848 - 854
  • [3] PD-1 inhibitors cause ILD in NSCLC patients with hypertension
    Reactions Weekly, 2022, 1925 (1) : 11 - 11
  • [4] Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC
    Leighl, N. B.
    Kuo, J.
    Pavel, A.
    Prescilla, M.
    Shepherd, F. A.
    Liu, G.
    Bradbury, P.
    Moskovits, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Impact of treatment with bilastine for PD-1/PD-L1 inhibitors induced rash
    Hirata, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Beyond PD-1 Blockade: Novel Checkpoint Inhibitors
    Rizvi, Naiyer A.
    ONCOLOGY-NEW YORK, 2020, 34 (12): : 553 - 556
  • [7] Rheumatologic symptoms in oncologic patients on PD-1 inhibitors
    Kuswanto, Wilson F.
    MacFarlane, Lindsey A.
    Gedmintas, Lydia
    Mulloy, Alexandra
    Choueiri, Toni K.
    Bermas, Bonnie L.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 47 (06) : 907 - 910
  • [8] Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving PD-1 Inhibitors for Metastatic NSCLC
    Poletes, C.
    Cheng, S. C.
    Zhan, L. J.
    Lee, J.
    Patel, D.
    Bradbury, P. A.
    Shepherd, F. A.
    Leighl, N. B.
    Sacher, A. G.
    Liu, G.
    Lau, S. C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S95 - S96
  • [9] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
  • [10] Spectrum of Early Progression in Advanced NSCLC Patients Treated with PD-1 Inhibitors: Identifying Markers for Poor Outcome
    Nishino, M.
    Adeni, A.
    Lydon, C.
    Hatabu, H.
    Janne, P.
    Hodi, F. S.
    Awad, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1914 - S1915
12345